Consolidated Clinical Trials CCT

Current Studies

2011-2016 Active Trials

TITLE OF STUDY

PHASE

INDICATION

STATUS

For definitions, visit Glossary

A Randomised, Double-blind, Chronic Dosing (56 week) Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab (MEDI-563) in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations

III

COPD

Ongoing/Currently Enrolling

A Randomized, Double-Blind, Multi-Center, Parallel Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD

III

COPD

Ongoing/Currently Enrolling

A comparative effectiveness and safety study of Arformoterol Tartrate inhalation solution and Tiotropium Bromide on re-hospitalization in chronic obstructive pulmonary disease (COPD) subjects

IV

COPD

Ongoing/Currently Enrolling

A randomized, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered by the Respimat® Inhaler with Tiotropium inhalation capsules 18 µg delivered by the HandiHaler®

III

COPD

Ongoing/Currently Enrolling

A 52 week, double blind, randomized, placebo controlled, parallel group study to evaluate the effect of Roflumilast 500 µg on exacerbation rate in patients with chronic obstructive pulmonary disease treated with a fixed dose combination of long acting beta agonist and inhaled corticosteroid.

III

COPD

Ongoing

A Multicentre, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-actingΒ2 Agonist

III

Asthma

Ongoing/Closed to Enrollment

A 52-week, multicenter, randomized, double-blind, placebo controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma

III

Asthma

Ongoing/Open to Enrollment

A Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid Use in Adults and Adolescents with Oral Corticosteroid dependent Asthma

III

Asthma

Ongoing/Open to Enrollment

Secretion mobilization in COPD

COPD Device

Ongoing/Currently Enrolling

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk

IV

Deep Vein Thrombosis

Ongoing/Open to Enrollment

Closed Studies

Visit Closed Studies

 
Copyright © 2006 - 2010 Consolidated Clinical Trials, Inc.   
Web Site Design by Randmdesign.com and Web-Makeovers.com